Breast cancer patients with vitamin D deficiency face dramatically more painful recoveries after surgery and consume substantially more opioid medication in the days following their procedures, according to new research published in Regional Anesthesia & Pain Medicine.
The finding emerges from a study of 184 women undergoing breast cancer surgery at Fayoum University Hospital in Egypt between September 2024 and April 2025. Half had vitamin D levels below 30 nmol/L, classified as deficiency, while the other half maintained adequate levels. The two groups were otherwise comparable, with average ages of 44 and 42 years.
During the first 24 hours after surgery, women with low vitamin D were three times more likely to experience moderate to severe pain compared with those having sufficient vitamin D. Researchers measured pain at multiple intervals, starting immediately after the operation and continuing at 6, 12, 18, and 24 hours. Notably, no patients in either group reported the highest pain levels, meaning the difference centered on moderate pain ranging from 4 to 6 on a 10-point scale.
The opioid gap between the two groups widened dramatically after surgery. While vitamin D deficient patients received modestly more fentanyl during the operation itself, averaging 8 micrograms more than those with adequate vitamin D, the postoperative difference became substantial. Patients with low vitamin D consumed an average of 112mg more tramadol than their counterparts, a patient-controlled opioid with doses capped at 50mg per hour.
Scientists increasingly recognize vitamin D as playing a central role in how the body perceives and manages pain. Researchers believe this connection stems from the vitamin's anti-inflammatory properties and its effects on immune system function. Vitamin D deficiency also occurs frequently among breast cancer patients, creating a potentially vulnerable population.
Greater opioid consumption carries real clinical consequences. These medications produce side effects including nausea, vomiting, drowsiness, and confusion. The study observed postoperative nausea occurred more frequently among vitamin D deficient patients, though vomiting appeared only in that group despite differences too small to reach statistical significance. Opioids also carry risks of dependence and addiction when used at higher doses.
Researchers acknowledged important limitations in their work. The study's observational design at a single medical center cannot definitively prove that low vitamin D directly caused the pain increase. The team did not measure inflammatory markers that might explain vitamin D's mechanism of action. Additionally, the study lacked data on patient anxiety, depression, cancer stage, previous treatments, and pre-surgery sleep quality, all factors potentially influencing pain perception.
Despite these constraints, the research team concluded that vitamin D deficiency correlates with higher moderate to severe postoperative pain and increased opioid use in breast cancer patients undergoing surgery. They suggested that preoperative vitamin D supplementation for patients with levels below 30 nmol/L may help modulate pain after the procedure.
The findings could reshape surgical preparation protocols for breast cancer patients, potentially offering a simple, low-cost intervention to reduce postoperative suffering and opioid dependence. If larger studies confirm these associations, screening and correcting vitamin D deficiency before surgery might become standard practice.
Author Jessica Williams: "A simple vitamin fix for one of cancer surgery's toughest problems deserves serious follow-up, especially given the epidemic of post-surgical opioid use."
Comments